SBIR funding by the NHLBI to Selexys results in the development of crizanlizumab. Selexys was founded in 2002 by Rodger (Rod) McEver, M.D., Richard Cummings, Ph.D., and Rick Alvarez, M.B.A. Read more here.
NHLBI funding leads to promising drug candidate to prevent sickle cell pain